Improved diagnostic and therapeutic options for patients living with ulcerative colitis and atopic dermatitis: this is the ultimate aim of the ImmUniverse project.
New insights into disease severity and progression will enable personalised therapy for each individual patient.
“Unlike previous studies in the field, we will specifically compare signatures from the same individual over time, capturing the full range of disease activity. We expect this approach to provide us with valuable insights into the interaction between the factors affecting disease progression and therapy response.”Professor Silvio Danese, ImmUniverse Coordinator
Professor of Gastroenterology at Humanitas University in Milan
Immune-mediated inflammatory diseases (IMIDs) result from abnormal activities of the body’s immune system. Ulcerative colitis and atopic dermatitis are part of this category of illnesses which are an increasing medical burden in industrialised countries worldwide. The enormous heterogeneity in disease outcome and response to targeted therapies makes it difficult to tailor the treatment of IMIDs to individual patients. This is where ImmUniverse aims at introducing ground-breaking new insights and practical improvements for patients.